| Message: | Pharmaceutical Raw Material CAS 73963-72-1 Cilostazol
Basic Information:
Product Name Cilostazol
CAS 73963-72-1
Assay 99.0%
Appearance White Crystalline Powder
Molecular Formula C20H27N5O2
Molecular weight 369.46
Grade Pharmaceutical Grade
Storage Shading, Confined Preservation
Product Description:
Cilostazol is a quinolinone-derivative medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal.
Cilostazol is a phosphodiesterase inhibitor with therapeutic focus on cyclic adenosine monophosphate (cAMP). It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation.
Clinical Uses:
Cilostazol is approved for the treatment of intermittent claudication. The typical dose is 100 mg twice a day. The effects may take as long as 3 months to be evident and has been shown to improve pain-free walking distance by 50%.
Cilostazol is also frequently used off-label, at the same dose, for treatment of intracranial atherosclerosis and secondary stroke prevention.
Cilostazol, clearly effective for a debilitating condition whose current treatment is often inadequate, is a member of a pharmacologic class that is dangerous to people with severe heart failure and unstudied in other people. Cilostazol has been studied in people without heart failure, without evidence of harm, but much more data would be needed to determine no risk exists.
Contact Person: Jack
Sky-pe: PharChemSteroid
Email: jack@chembj.com
WhatsApp: +8617327096097 |
my account
